Navigation Links
Biopure Reaffirms Strategy Following Recent NIH/FDA Workshop
Date:5/7/2008

Panel on Hemoglobin-Based Oxygen Carriers Indicates Support for Continued

Investigational Use Where Blood Is Not an Option

CAMBRIDGE, Mass., May 7 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the Company's strategy to pursue indications for its product Hemopure(R) [hemoglobin glutamer-250 (bovine)] , or HBOC-201, when blood is not an option was reinforced by the National Institutes of Health/Food and Drug Administration (NIH/FDA) recent workshop. The workshop, entitled "The Safety of Hemoglobin-based Oxygen Carriers," took place on April 29 and 30, 2008 in Bethesda, Maryland. The purpose of a public workshop is to discuss issues in featured presentations and roundtable discussions led by experts from academic institutions, government, and industry. No actions are typically taken at workshops. The transcript is expected to be available on the FDA website by late May 2008.

"A number of participants in this important workshop recognize the therapeutic potential that Hemoglobin-based Oxygen Carriers (HBOCs) offer to patients who may not have the option of receiving packed red blood cells," said Biopure Chairman and CEO Zafiris G. Zafirelis. "The company's initial strategy with Hemopure was to develop indications in the treatment of adult surgical patients who are acutely anemic, as in South Africa, where Hemopure has market authorization and is being used clinically. We also believe there are excellent applications for its use where blood is not indicated, and in out-of-hospital treatment of trauma patients in hemorrhagic shock, where red blood cells are not available."

Biopure Vice President of Medical Affairs Dr. A. Gerson Greenburg delivered the company's presentation,
'/>"/>

SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Biopure Announces Reverse Stock Split
2. Biopures Stock Symbol Reverts to BPUR
3. Biopure Announces Closing of $14.9 Million Financing
4. Four Abstracts by Biopure and Collaborating Scientists Accepted for Annual Meeting of American Society for Clinical Pharmacology and Therapeutics
5. Biopure Announces 2007 Fourth Quarter and Year-End Financial Results
6. Biopure Receives Comment Letter From U.K. Regulatory Body on Marketing Application for Hemopure(R)
7. New Study of Aspartame Research Reaffirms Safety, Even Among Heaviest Users
8. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
9. Hanger Orthopedic Group, Inc. Announces Senior Leadership Succession Plan and Reaffirms Guidance
10. Accipiter Capital Management Reaffirms Its Opposition to the Acquisition of VistaCare, Inc. by Odyssey Healthcare, Inc.
11. Omnicell Announces Common Stock Repurchase Program; Reaffirms Earnings Forecast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... NY (PRWEB) October 20, 2014 ... non-profit organization that helps New Yorkers living with ... changes toward health, housing, recovery and self-sufficiency. Each ... transformed the local community through their tireless efforts. ... Marc Shapses , has been selected as ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 Zereana Jess-Huff, a ... Mrs. Maryland 2014 on a platform to think outside the ... and uses her position to raise awareness about women’s other ... for breast cancer. You say the color pink and everybody ... know for a fact that it has not been won ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... CO (PRWEB) October 20, 2014 ... assays are the only imaging assays capable of ... a single test.  With these three dimensions of ... ability to detect the widest range of disease-causing ... usually missed by other genomic tools, including today’s ...
(Date:10/20/2014)... October 20, 2014 It’s hard to imagine ... orphans and vulnerable children around the world, it’s a reality. ... people, many children are forced to walk barefoot on rocky ... families or play with their friends. , Buckner International's ... Air1 Radio in October to encourage support for ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 2Health News:Buckner Shoes for Orphan Souls® Garners Support from Air1 Radio 3
... magnetic resonance imaging (MRI) may help physicians differentiate between ... wrist enabling more targeted therapies unique to each condition, ... the American Journal of Roentgenology . Contrast-enhanced MRI ... bodily structures. Rheumatoid arthritis ...
... ... ... ... ...
... ... ... , ... SPOKANE, Wash. , Feb. 18 On January 29, 2010 , Sacred Heart Medical Center was cited and ...
... cooling devices, , THURSDAY, Feb. 18 (HealthDay News) -- ... keep vaccines stable without the use of refrigerators or ... , The vaccine storage technology, developed by scientists ... could help eliminate the need for refrigeration, which is ...
... Feb. 18 WebMD Health Corp. (Nasdaq: WBMD ), ... three months and year ended December 31, 2009 . , For ... was $138.1 million , compared to $110.1 million in ... interest, taxes, non-cash and other items ("Adjusted EBITDA") was $46.4 million ...
... After testing dozens of samples from marine mammals, University ... be the ideal model for the study of cervical ... multiple infections of apillomaviruses, which are known to be ... a marine mammal biologist and clinical assistant professor at ...
Cached Medicine News:Health News:Contrast-enhanced MRI could play a key role in differentiating between common types of arthritis 2Health News:NOVAVAX, Inc. Receives NASDAQ Non-Compliance Letter 2Health News:NOVAVAX, Inc. Receives NASDAQ Non-Compliance Letter 3Health News:NOVAVAX, Inc. Receives NASDAQ Non-Compliance Letter 4Health News:Sacred Heart Medical Center Cited for Violation of Safety Standards in H1N1 Prevention 2Health News:Sacred Heart Medical Center Cited for Violation of Safety Standards in H1N1 Prevention 3Health News:New Technology Could Widen Reach of Vaccines 2Health News:WebMD Announces Fourth Quarter Financial Results 2Health News:WebMD Announces Fourth Quarter Financial Results 3Health News:WebMD Announces Fourth Quarter Financial Results 4Health News:WebMD Announces Fourth Quarter Financial Results 5Health News:WebMD Announces Fourth Quarter Financial Results 6Health News:WebMD Announces Fourth Quarter Financial Results 7Health News:WebMD Announces Fourth Quarter Financial Results 8Health News:WebMD Announces Fourth Quarter Financial Results 9Health News:WebMD Announces Fourth Quarter Financial Results 10Health News:WebMD Announces Fourth Quarter Financial Results 11Health News:WebMD Announces Fourth Quarter Financial Results 12Health News:WebMD Announces Fourth Quarter Financial Results 13Health News:WebMD Announces Fourth Quarter Financial Results 14Health News:WebMD Announces Fourth Quarter Financial Results 15Health News:WebMD Announces Fourth Quarter Financial Results 16Health News:WebMD Announces Fourth Quarter Financial Results 17Health News:WebMD Announces Fourth Quarter Financial Results 18Health News:WebMD Announces Fourth Quarter Financial Results 19Health News:WebMD Announces Fourth Quarter Financial Results 20Health News:WebMD Announces Fourth Quarter Financial Results 21Health News:WebMD Announces Fourth Quarter Financial Results 22Health News:WebMD Announces Fourth Quarter Financial Results 23Health News:WebMD Announces Fourth Quarter Financial Results 24Health News:WebMD Announces Fourth Quarter Financial Results 25Health News:WebMD Announces Fourth Quarter Financial Results 26Health News:WebMD Announces Fourth Quarter Financial Results 27Health News:WebMD Announces Fourth Quarter Financial Results 28Health News:WebMD Announces Fourth Quarter Financial Results 29
(Date:10/20/2014)... -- Pharmaceutic Labs announces the opening of its specialty ... for admixing, compounding, drug shortages and clinical ... FDA standards for safety and quality, using 21 CFR ... The 10,000 square foot outsourcing facility was designed ... quality control. The company will produce sterile and non-sterile ...
(Date:10/20/2014)... and RALEIGH, N.C., Oct. 20, 2014  BioPontis Alliance ... (HNF), both philanthropies, announced today the creation of ... the treatment of the rare disease known as ... announced its alliance model earlier this month. Today,s ... of a collaborative model where researchers and all ...
(Date:10/19/2014)... , Oct. 19, 2014  Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, animal ... invested in Iwase Dental Supply, Inc., a leading full-service ... transaction marks Henry Schein,s entrance into Japan ... market, and increases to 28 the number of countries ...
Breaking Medicine Technology:The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 2The Hereditary Neuropathy Foundation and BioPontis Alliance for Rare Disease Partner to Develop Treatments for Charcot-Marie-Tooth 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 2Henry Schein Enters Japan With Investment in Iwase Dental Supply 3Henry Schein Enters Japan With Investment in Iwase Dental Supply 4Henry Schein Enters Japan With Investment in Iwase Dental Supply 5
... June 28, 2011 The Mirixa Corporation and ... are pleased to announce that MirixaPro(SM), a Web-based ... patient care service delivery, will be deployed in ... agreement enabling CACDS to use a scalable, localized ...
... 2011 ,   The ... range of,new clinical data. The "Late-Breaking Clinical Trials" were ... SHPT study,(Evaluation of the Effectiveness of Paricalcitol Versus Cinacalcet,With ... June the,principal investigator of this study, Prof. Markus Ketteler,(Coburg, ...
Cached Medicine Technology:Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform 2Mirixa and CACDS Sign Agreement for Clinical Service Delivery Platform 3Update on IMPACT Study Results 2
... Diagnostics offers Q Fever IFA Test Kits ... and IgM human antibody responses to Coxiella ... the simultaneous semi-quantitative detection and differentiation of ... Phase II antigens. By providing the two ...
Claes Shielded Retinotomy Scissors, Vertical...
... is intended for qualitatively detecting antibodies to ... The test is indicated for testing persons ... aid in the presumptive laboratory diagnosis of ... for self-testing, and this test is not ...
... test for the detection and semi-quantitation of ... Encephalitis virus (SLE), Western Equine Encephalitis virus ... California Encephalitis/La Crosse virus (CE). Each kit ... spots of SLE, WEE, EEE, and CE ...
Medicine Products: